Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with onset or first recognition during pregnancy.
Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios.
Overt diabetes mellitus may be found in women presenting with risk factors for type 2 diabetes during the first prenatal visit (before 13 weeks of gestation).
Undergoing in-facility physical activity (PA) programmes initiated before the 20th week of gestation helps reduce the risk of developing gestational diabetes mellitus (GDM) among high-risk mothers, according to the results of a meta-analysis.
Women with high levels of very low-density lipoprotein cholesterol or high apolipoprotein B to A-1 ratio may fare better with insulin than metformin, with a recent study showing that treatment with the latter leads to higher serum concentrations of triglyceride-rich lipoproteins in the last trimester of pregnancy.
Women who follow a healthy plant-based diet before pregnancy have a lower risk of developing gestational diabetes mellitus (GDM), suggests a large, prospective cohort study presented at the ADA 2020 Annual Meeting.
For working expectant moms with gestational diabetes mellitus (GDM) who need additional support to control their blood sugar, a GDM management smartphone app is the way to go, according to a Singapore study.
Overweight or obese women with gestational diabetes mellitus (GDM) may fare well with metformin treatment, which is reported in a recent study to safely and effectively prevent excessive and promote adequate gestational weight gain (GWG) independent of age, body mass index (BMI) and timing of GDM diagnosis, among others.
Women who conceive singleton pregnancies following assisted reproductive technology (ART) may have a higher risk of developing gestational diabetes than those who conceive spontaneously, according to results of a systematic review and meta-analysis presented at EASD 2019.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.